KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-Current Debt (2016 - 2025)

Ionis Pharmaceuticals (IONS) has disclosed Non-Current Debt for 17 consecutive years, with $28.1 million as the latest value for Q4 2025.

  • For Q4 2025, Non-Current Debt fell 45.85% year-over-year to $28.1 million; the TTM value through Dec 2025 reached $28.1 million, down 45.85%, while the annual FY2025 figure was $28.1 million, 45.85% down from the prior year.
  • Non-Current Debt hit $28.1 million in Q4 2025 for Ionis Pharmaceuticals, down from $51.9 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $60.0 million in Q2 2021 and bottomed at $8.8 million in Q1 2023.
  • Average Non-Current Debt over 5 years is $37.9 million, with a median of $35.0 million recorded in 2023.
  • Year-over-year, Non-Current Debt surged 172.69% in 2022 and then plummeted 85.18% in 2023.
  • Ionis Pharmaceuticals' Non-Current Debt stood at $59.7 million in 2021, then plummeted by 73.25% to $16.0 million in 2022, then soared by 161.92% to $41.8 million in 2023, then rose by 24.11% to $51.9 million in 2024, then plummeted by 45.85% to $28.1 million in 2025.
  • According to Business Quant data, Non-Current Debt over the past three periods came in at $28.1 million, $51.9 million, and $41.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.